Humana is replacing the financial partner behind nearly 150 CenterWell senior primary-care clinics with BlackRock, a $2.8 billion restructuring designed to reduce balance-sheet obligations while keeping the insurer in control of daily operations.
Funds managed by HPS Investment Partners, part of BlackRock, will acquire Welsh, Carson, Anderson & Stowe's existing majority interest. CenterWell will remain the minority owner and continue managing the clinics, so Humana is changing the financing structure rather than exiting the care-delivery business. Closing is expected in the fourth quarter, subject to customary conditions and regulatory approvals.
The most important change is the removal of a put option in the earlier joint venture. That provision could have required Humana to buy the partner's stake at a predetermined price. Under the new structure, CenterWell can begin purchasing clinics from the venture in 2028. If clinics remain at the end of 2033, BlackRock may seek an exit, with CenterWell holding a first-offer right.
Removing the put option should reduce liabilities and make Humana's future funding requirements less rigid. The company also expects a lower cost of capital and additional financing capacity for clinic construction and acquisitions. BlackRock will own the majority, however, so the benefits depend on the full economics and protections in agreements that have not been publicly detailed.
The transaction fits Humana's broader effort to combine Medicare Advantage insurance with senior-focused primary care. CenterWell and Conviva operate more than 350 senior primary-care locations, giving Humana a platform to influence care coordination and medical costs. That strategic logic is valuable, but it also exposes the company to execution risk in operating clinics while its insurance business works through elevated medical spending.
Humana said the deal should not materially affect its 2026 adjusted earnings guidance. Investors therefore should treat it as a balance-sheet and growth-capital change, not an immediate earnings catalyst. The closing terms and future clinic expansion will determine whether the lower-cost structure produces durable returns.